Johnson & partners ( J&J ) will invest $ 500 m to eliminate malaria and tuberculosis by 2030 . The company announced it will appoint a research team to use J&J 's expertise and decades of experience with the two diseases to identify , develop and deliver next - generation vaccines and treatments . The initiative will also implement the UN 's Sustainable Development Goal 3 mandate , and includes the Janssen vaccine Companies ' investigational mosaic - funded global vaccine trial .
Johnson & Johnson (J&J) will invest $500m to eliminate HIV and tuberculosis by 2030. The company said it will appoint a research team to use J&J's resources and decades of experience with the two diseases to identify, develop and deliver next-generation vaccines and treatments. The initiative will also fulfil the UN's Sustainable Development Goal 3 targets, and includes the Janssen Pharmaceutical Companies' investigational mosaic-based global vaccine trial.